Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.
We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.
We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.
Lapatinib could be considered cost-effective inIreland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.
The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.